Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Autor: Kwakman, Johannes J.M., Vink, G., Vestjens, J. H., Beerepoot, L. V., de Groot, J. W., Jansen, R. L., Opdam, F. L., Boot, H., Creemers, G. J., van Rooijen, J. M., Los, M., Vulink, A. J.E., Schut, H., van Meerten, E., Baars, A., Hamberg, P., Kapiteijn, E., Sommeijer, D. W., Punt, C. J.A., Koopman, M., Sub Tolakker, Afd Pedagogiek in diverse samenlevingen, Methodology and statistics for the behavioural and social sciences
Přispěvatelé: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Interne Geneeskunde, Oncology, CCA - Cancer Treatment and Quality of Life, Sub Tolakker, Afd Pedagogiek in diverse samenlevingen, Methodology and statistics for the behavioural and social sciences, Medical Oncology
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
THYMIDINE PHOSPHORYLASE
PREDICTOR
Pyrrolidines
ANTITUMOR-ACTIVITY
ECOG Performance Status
Trifluridine
chemistry.chemical_compound
0302 clinical medicine
QUALITY-OF-LIFE
Antineoplastic Combined Chemotherapy Protocols
Netherlands
Aged
80 and over
education.field_of_study
Metastatic colorectal cancer
Trifluridine/tipiracil
Feasibility
Hematology
General Medicine
Middle Aged
Prognosis
TAS-102
Drug Combinations
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
SURVIVAL
Population study
Original Article
Female
TRIAL
Colorectal Neoplasms
medicine.drug
Adult
medicine.medical_specialty
Anemia
Population
Neutropenia
Disease-Free Survival
03 medical and health sciences
SDG 3 - Good Health and Well-being
NEUTROPENIA
Internal medicine
PERFORMANCE STATUS
medicine
Humans
Compassionate use
Uracil
education
Aged
Tipiracil
Performance status
business.industry
Leukopenia
medicine.disease
EFFICACY
030104 developmental biology
chemistry
Surgery
business
Thymine
Zdroj: International Journal of Clinical Oncology, 23(3), 482-489. Springer
International journal of clinical oncology / Japan Society of Clinical Oncology, 23(3), 482-489. Springer Japan
International Journal of Clinical Oncology, 23(3), 482
International Journal of Clinical Oncology
International Journal of Clinical Oncology, 23(3), 482-489. Springer Japan
International Journal of Clinical Oncology, 23(3), 482-489
ISSN: 1437-7772
1341-9625
Popis: BACKGROUND The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands. METHODS Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival (OS). RESULTS A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 1.8-2.3) and 5.4 months (95% CI, 4.0-6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) compared to patients with ECOG PS 0-1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS. CONCLUSIONS Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences in patient characteristics between our population and the RECOURSE study population should be taken into account in the interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2. FUNDING Johannes J.M. Kwakman received an unrestricted research grant from Servier.
Databáze: OpenAIRE
Externí odkaz: